163 related articles for article (PubMed ID: 21052616)
1. [Evaluation of a dominant-negative recombinant herpes simplex virus (HSV) type 1 as a vaccine against genital herpes in mice und guinea pigs].
Brans R
Hautarzt; 2010 Dec; 61(12):1073-8. PubMed ID: 21052616
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.
Brans R; Yao F
BMC Microbiol; 2010 Jun; 10():163. PubMed ID: 20525279
[TBL] [Abstract][Full Text] [Related]
3. Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1.
Brans R; Akhrameyeva NV; Yao F
J Invest Dermatol; 2009 Oct; 129(10):2470-9. PubMed ID: 19357711
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
5. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
Awasthi S; Huang J; Shaw C; Friedman HM
J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.
Awasthi S; Lubinski JM; Shaw CE; Barrett SM; Cai M; Wang F; Betts M; Kingsley S; Distefano DJ; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
J Virol; 2011 Oct; 85(20):10472-86. PubMed ID: 21813597
[TBL] [Abstract][Full Text] [Related]
7. A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs.
Zhang P; Xie L; Balliet JW; Casimiro DR; Yao F
PLoS One; 2014; 9(6):e101373. PubMed ID: 24979708
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a dominant-negative recombinant HSV type 1 protects against HSV-1 skin disease in guinea pigs.
Brans R; Eriksson E; Yao F
J Invest Dermatol; 2008 Dec; 128(12):2825-32. PubMed ID: 18496565
[TBL] [Abstract][Full Text] [Related]
9. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.
Halford WP; Püschel R; Gershburg E; Wilber A; Gershburg S; Rakowski B
PLoS One; 2011 Mar; 6(3):e17748. PubMed ID: 21412438
[TBL] [Abstract][Full Text] [Related]
10. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
11. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease.
Da Costa XJ; Bourne N; Stanberry LR; Knipe DM
Virology; 1997 May; 232(1):1-12. PubMed ID: 9185583
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
[TBL] [Abstract][Full Text] [Related]
13. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.
Akhrameyeva NV; Zhang P; Sugiyama N; Behar SM; Yao F
J Virol; 2011 May; 85(10):5036-47. PubMed ID: 21389121
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
15. High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.
Lu Z; Brans R; Akhrameyeva NV; Murakami N; Xu X; Yao F
J Invest Dermatol; 2009 May; 129(5):1174-84. PubMed ID: 19005489
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
[TBL] [Abstract][Full Text] [Related]
17. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.
Natuk RJ; Cooper D; Guo M; Calderon P; Wright KJ; Nasar F; Witko S; Pawlyk D; Lee M; DeStefano J; Tummolo D; Abramovitz AS; Gangolli S; Kalyan N; Clarke DK; Hendry RM; Eldridge JH; Udem SA; Kowalski J
J Virol; 2006 May; 80(9):4447-57. PubMed ID: 16611905
[TBL] [Abstract][Full Text] [Related]
18. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
Bettahi I; Zhang X; Afifi RE; BenMohamed L
Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
[TBL] [Abstract][Full Text] [Related]
19. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.
Hoshino Y; Pesnicak L; Dowdell KC; Burbelo PD; Knipe DM; Straus SE; Cohen JI
J Infect Dis; 2009 Oct; 200(7):1088-95. PubMed ID: 19702506
[TBL] [Abstract][Full Text] [Related]
20. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
